Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 59.3141
- Book/Share 20.4356
- PB 31.2137
- Debt/Equity 1.8705
- CurrentRatio 1.2777
- ROIC 0.2757
- MktCap 601208415540.0
- FreeCF/Share 2.0198
- PFCF 331.5
- PE 41.331
- Debt/Assets 0.3387
- DivYield 0.0088
- ROE 0.8836
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Published: March 07, 2025 by: FXEmpire
Sentiment: Neutral
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
Read More
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
Published: March 07, 2025 by: Benzinga
Sentiment: Neutral
The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcare supply chain.
Read More
US judge denies injunction to stop bar on copies of Lilly weight loss drug
Published: March 06, 2025 by: Reuters
Sentiment: Neutral
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.
Read More
The Big 3: EBAY, SLV, LLY
Published: March 05, 2025 by: Schwab Network
Sentiment: Neutral
@Theotrade's Don Kaufman remains bullish on the iShares Silver Trust ETF (SLV) but shares bearishness on eBay Inc. (EBAY) and Eli Lilly (LLY). He also offers example options trades for all three names.
Read More
Lilly to participate in Leerink Partners Global Healthcare Conference
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 9:20 a.m.
Read More
Eli Lilly investing $27B more in US manufacturing
Published: February 27, 2025 by: Fox Business
Sentiment: Positive
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.
Read More
Eli Lilly Latest US Company to Commit to Domestic Investments
Published: February 26, 2025 by: Investopedia
Sentiment: Negative
Eli Lilly (LLY) plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S., as the company looks to ramp up its domestic drug productions amid the threat of possible tariffs.
Read More
Eli Lilly announces $27B investment in US drug manufacturing
Published: February 26, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) plans to invest at least $27 billion in four new US manufacturing facilities, the company announced during an event in Washington DC. Three of the facilities will focus on producing active pharmaceutical ingredients (APIs) for drugs like Zepbound and Mounjaro, while the fourth will expand the company's capacity for future injectable medications.
Read More
Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites
Published: February 26, 2025 by: Market Watch
Sentiment: Positive
Eli Lilly & Co.'s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.
Read More
Eli Lilly CEO on $27 billion in new U.S. manufacturing investments
Published: February 26, 2025 by: CNBC Television
Sentiment: Positive
Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company develops new drugs.
Read More
Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients
Published: February 25, 2025 by: Investopedia
Sentiment: Neutral
Eli Lilly (LLY) on Tuesday lowered the price of its weight-loss drug Zepbound for some patients paying out of pocket and introduced two new available vial doses.
Read More
Why Eli Lilly Stock Popped Today
Published: February 25, 2025 by: The Motley Fool
Sentiment: Positive
Eli Lilly (LLY 2.10%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases.
Read More
Eli Lilly: Load Up Before It Leaves You Behind
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly investors have been "quietly" loading up, as the stock outperformed the S&P 500. Lilly has been making gains against Novo Nordisk, and the advance may not be over. Policy risks and pricing changes could be risks to consider later, but the stock is still assessed to be undervalued when we consider LLY's PEG ratio.
Read More
Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients
Published: February 25, 2025 by: Market Watch
Sentiment: Positive
The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.
Read More
Eli Lilly Unveils Higher Single-Dose Zepbound Vials for $499 a Month
Published: February 25, 2025 by: Barrons
Sentiment: Positive
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
Read More
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
Published: February 24, 2025 by: 24/7 Wall Street
Sentiment: Negative
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over.
Read More
This Growth Stock Surged 63% in 2024. Here's Why 2025 Could Bring An Even Bigger Gain.
Published: February 21, 2025 by: 24/7 Wall Street
Sentiment: Positive
The big pharma sector is one that's generally fallen out of favor for many investors over the past few decades, as large healthcare companies have seen slower growth and consolidation hasn't generally provided the kind of upside investors had grown accustomed to over the latter half of the past century.
Read More
Grok 3 makes ideal stock portfolio for 2025
Published: February 21, 2025 by: Finbold
Sentiment: Positive
Artificial intelligence (AI) platforms have been enjoying the spotlight since the original release of ChatGPT in late 2022 and have started gaining increasing traction among investors for apparently outperforming a significant portion of professional managers.
Read More
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Published: February 20, 2025 by: Reuters
Sentiment: Positive
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements, a filing showed on Wednesday.
Read More
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall
Published: February 20, 2025 by: CNBC
Sentiment: Positive
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the company's Chief Scientific Officer Dan Skovronsky.
Read More
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Published: February 20, 2025 by: CNBC
Sentiment: Positive
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent drugs are two areas where Lilly is focusing.
Read More
3 Stocks That Could Trounce the Market in 2025
Published: February 17, 2025 by: The Motley Fool
Sentiment: Positive
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Read More
Calls of the Day: Live Nation, Eli Lilly, AT&T, Adobe and Astera Labs
Published: February 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss the latest Calls of the Day.
Read More
LLY Rises More Than 4% in a Week: How to Play the Stock
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Read More
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Published: February 13, 2025 by: MarketBeat
Sentiment: Positive
Eli Lilly and Company NYSE: LLY is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close.
Read More
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Published: February 13, 2025 by: The Motley Fool
Sentiment: Positive
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (LLY 0.92%) announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000